The consolidation amid range-bound trading may continue in the upcoming sessions due to a lack of triggers. Below are some short-term trading ideas to consider.

Trade Spotlight: How should you trade Federal Bank, NALCO, Eternal, KEI Industries, Karur Vysya Bank, and others on October 09?

The market is expected to consolidate further until a decisive breakout above the previous day's high occurs. Below are some short-term trading ideas to consider.

Trade Spotlight: How should you trade Zensar Technologies, APL Apollo Tubes, ITC, CRISIL, BSE, Aurobindo Pharma, and others on May 9?

The market is expected to see further weakness if it decisively breaks the previous day's low. Below are some short-term trading ideas to consider.

Trade Spotlight: How should you trade Valor Estate, Cholamandalam Financial, ITC, Clean Science, Deepak Fertilisers, Gujarat Gas, and others on April 15?

The market mood is likely to remain upbeat in the upcoming session. Below are some trading ideas for the near term.

Trade Spotlight: How should you trade ONGC, United Spirits, Action Construction Equipment, Gland Pharma, Blue Star, and others on January 2?

Rangebound trading is expected to sustain in the upcoming sessions until the frontline indices give a strong close above all key moving averages. Below are some trading ideas for the near term.

Trade Spotlight: How should you trade Paytm, Coal India, HPCL, Uno Minda, Amber Enterprises, Oberoi Realty, and others on December 26?

The market is expected to attempt an upward movement amid likely consolidation. Below are some trading ideas for the near term.

Top 24 stocks to buy, sell and avoid in the coming market correction

Immediate support for the Nifty 50 is seen at 25,700, with a crucial level at 25,500, while resistance is expected around the 25,900-26,000 range. Here’s a look at the ‘buy on dip’ opportunities and stocks to avoid, according to market experts.

Trade Spotlight: How should you trade Blue Star, Sun Pharma, BSE, Gujarat Pipavav Port, Aurobindo, and others on Wednesday?

Experts suggest that the Nifty 50 is likely to find support at 24,100, and below this, the 24,000-23,900 zone will be crucial to watch. However, resistance is expected at 24,300 on the higher side. Here are some trading ideas for the near term.

Trade Spotlight: How should you trade Britannia, SAIL, BHEL, Indian Bank, Lupin and others?

The market is expected to consolidate in the coming sessions, though the overall trend remains in favour of bulls.

Trade Spotlight: How should you trade Aurobindo, Tech Mahindra, TVS Motor, MTAR Tech and others?

The upward move towards a record high is expected to be seen in the coming sessions.

Top 10 stock ideas for May series when D-St bulls charge Nifty towards 22,800

As long as the Nifty 50 holds 22,300-22,200 levels on closing basis, the upward march towards 22,800 can't be ruled out in the coming sessions.

Short-term picks: Three stocks that may generate 17-25% returns in next 2-3 weeks

In terms of levels, immediate resistance is identified at 22,530, a level of significant importance on higher time frames, with further resistance seen at 22,800 followed by 23,170 for the Nifty.

Hot Stocks | Bet on Aurobindo Pharma, Tata Comm, Just Dial for healthy returns

The daily bullish candle and the hourly chart's pattern of higher-highs, higher-lows affirms the robust outlook, with the next rally potentially targeting the 22,300-22,350 range

Hot Stocks | Hind Copper, Cyient, Aurobindo Pharma may deliver double-digit gains

In light of the overall chart structure, Vidnyan Sawant maintains a bullish stance on Nifty 50 with specific targets set at 21,593 and 21,800 for the short to medium term.

Trade Spotlight | Your strategy for Cyient, GE Shipping, Aurobindo Pharma today

Great Eastern Shipping Company shares rose nearly 4 percent to Rs 624 and formed long bullish candlestick pattern on the daily timeframe with above average volumes.

Hot Stocks | Here's why HDFC Bank and Aurobindo Pharma are good short-term bets

The immediate support for the Nifty is placed near 16,400 level and resistance is pegged near 16,900 level, said Rohan Patil of Bonanza Portfolio

Union Budget 2021 likely to focus on infra, healthcare; analysts see these 10 stocks gaining

D-Street is counting on key reforms in the Budget that could push growth and kicks tart the capex cycle in the economy.

Hot Stocks | Can bet on Muthoot Finance, Lupin and Aurobindo Pharma for short term

On the derivative front, Put writers have been continuously adding up hefty open interest at 14,000 and 14,100 strikes which indicates limited downside in Nifty as of now.

Hot Stocks | Can bet on Aurobindo Pharma, Sun Pharma and Maharashtra Seamless for short term

On the technical front, secondary oscillators suggest that markets are likely to remain volatile in the coming sessions with wild swings on both sides.

Brokerages upgraded these 35 stocks in November; expect returns up to 40%

The most noted point after September quarter earnings season was that more than 100 stocks witnessed upgrade in rating to buy from brokerages.

Market to remain volatile till US elections, these 18 stocks can give 10-37% return

Long-term investors should pick their favourite mid and smallcap shares gradually over the next few months, experts say.

Hot Stocks | Aurobindo Pharma, Cummins India, LIC Housing Finance can give up to 12% return in short-term

Nifty registered a high above its previous double top resistance which indicates the continuation of higher high higher bottom formation on the daily timeframe.

Nifty may move towards 11,200 by week end; RIL likely to hit fresh record high: Globe Capital

We would advise to buy Bank Nifty on some dips towards 21,300 for targets of 21,750-21,800.

After a strong Q4 FY20, these 5 companies can return 10-30%

The brokerage now expects Nifty earnings to grow at a CAGR of 16 percent over FY20-22, albeit on a low base and values the Nifty at 10,300 i.e. 1.2x PEG on FY22E EPS of Rs 543 with corresponding Sensex target placed at 34,800.

Pharma: Is the show over or are there some fireworks left?

After some tough years, the pharma sector is performing well and is around 25 percent up while the broader market is down 20 percent year-to-date.